高初蕾 华创证券分析师: 基药政策专家石老师: 信号不通畅。 好的，各位领导，大家晚上好。我是华创医药的中药研究员高出磊，欢迎大家来参加由我 们团队主办的基药目录管理办法专家解读会那首先也感谢大家这么晚还来参加我们的专家 会。那今天傍晚我们看到卫健委联合 10 个部委共同印发了基药目录管理办法。非常的振 奋人心，确实是大家期盼了 4~5 年的政策终于有了一个明确的启动和催化。那今天我们团 队也是第一时间邀请专家来为我们做一个解读。因为今天时间比较晚，我希望咱们的专家 会还是尽量能够高效简短，希望各位领导如果有问题，也能尽早的提问，私信或者线上留 言都可以。 那首先我们先请专家就此次基药目录管理办法的这个文件上面表述的一些变化，未来政策 推进的节点，哪些品种进入的概率更大，以及后续执行后落地的配套政策等等，这些大家 比较关心的核心问题，来给大家做一个分享。那在专家分享之前，我也想提醒各位投资者 因为政策的方向比较难去预测，那我们希望专家的观点也仅供各位领导来参考。具体以最 后卫健委出台的目录为准，那我们也欢迎专家的时间，有请您来给我们做一个介绍。 基药政策专家石老师: 是。在线的各位老师好，今天是这个，政策一出 ...

Summary of Key Points from Conference Call Records Industry Overview - **Industry**: Innovative Pharmaceuticals - **Global Drug Approvals**: In 2025, a total of 46 new drugs were approved globally, which is a decrease from the previous two years but still above the historical average of 36 since 1993 [1][2] - **Trends**: The approval landscape is shifting towards precision medicine and unmet medical needs, particularly in oncology, where 16 drugs were approved, representing approximately 15% of total approvals, higher than the past five-year average [4] Core Insights and Arguments - **FDA Performance**: Despite personnel turnover and regulatory challenges, the FDA maintained high output efficiency, approving 46 new drugs in 2025, including 34 new molecular entities and 12 biologics [2] - **Emerging Technologies**: The FDA is advancing platforms such as Antibody-Drug Conjugates (ADC) and bispecific antibodies, with ADC becoming a cornerstone in oncology [5][29] - **China's Global Integration**: In 2025, China saw a significant increase in license-out transactions, with 154 deals worth $14.19 billion, marking a 46.7% and 150% year-over-year increase, respectively [6][31] - **Clinical Trial Quality**: China's clinical trial quality has improved significantly, with compliance rates surpassing those of Europe and the U.S., addressing international concerns about data reliability [10] Company-Specific Developments - **Innovative Drug Companies**: - **Kangfang Biotech**: Achieved significant progress with its EVSTAN antibody, showing superior progression-free survival (PFS) and overall survival (OS) benefits [11] - **Hanyu Pharmaceutical**: Reported impressive results for its independent monoclonal antibody for ESCC, with a two-year overall survival rate of 88.3% [12] - **Hengrui Medicine**: Advanced in ADC technology, evolving to XDC, and has multiple ADC drugs in late-stage clinical trials [14] - **Rongchang Biotech**: Plans to expand indications for its core product, with several key clinical data expected in 2027 [15] - **Kelong Botai**: Entered the global registration phase for its lung cancer drug, FKB267, with significant data disclosures [16] - **Baiyi Shenzhou**: Made strides in hematology with multiple important data readouts [17][18] Additional Important Insights - **Market Positioning**: China's position in the global transaction market has significantly improved, with 339 transactions recorded in 2025, accounting for 24.5% of the global market [7][8] - **Regulatory Environment**: The FDA's stable policies and efficiency improvements are expected to facilitate the entry of innovative products from China into overseas markets [31] - **Emerging Drug Classes**: ADCs and similar conjugates are identified as the most certain and highest pricing power segments in the global innovative drug market [29][30] This summary encapsulates the key points from the conference call records, highlighting the innovative pharmaceutical industry's dynamics, regulatory environment, and specific company advancements.

Core Viewpoint - Gilead Sciences (GILD.US) shares rose over 5% to a record high of $155.54 following the release of its financial results, indicating strong performance and growth potential in the market [1] Financial Performance - For the full year 2025, Gilead reported total revenue of $29.443 billion, representing a year-over-year increase of 2.4% [1] - The net profit attributable to the company was $8.51 billion, showing a significant year-over-year increase of approximately 16.73 times [1] - Non-GAAP diluted earnings per share reached $8.15, reflecting a substantial year-over-year growth of 77% [1] Product Development and Market Position - Gilead's Chairman and CEO, Daniel O'Day, highlighted that the previous year was fruitful for the company, marked by the successful launch of Yeztugo, the world's first semi-annual HIV prevention therapy [1] - The continued growth of Biktarvy and Descovy has established a solid foundation for the company's future growth [1]

Core Viewpoint - Gilead Sciences (GILD.US) shares rose by 5.8%, reaching a historical high of $155.75 following the release of its Q4 earnings report, which exceeded analyst expectations [1] Financial Performance - The company reported Q4 revenue of $7.9 billion, a 5% year-over-year increase, surpassing analyst expectations of $7.7 billion [1] - Adjusted earnings per share (EPS) were $1.86, exceeding the forecast of $1.81 [1] Product Sales - Sales of HIV-related products increased by 6% year-over-year to $5.8 billion, driven primarily by rising demand for prevention and treatment [1]

据港交所文件：浙江京新药业股份有限公司向港交所提交上市申请书。 来源：滚动播报 ...

Core Viewpoint - The increasing trend of funds focusing on inquiry transfer projects, which offer shorter cycles and greater discounts, is aimed at enhancing capital utilization efficiency [1]. Group 1: Market Trends - Since 2026, 12 listed companies have conducted inquiry transfers, with notable participation from well-known public and private fund institutions such as E Fund, Huaxia Fund, and Nord Fund [1][2]. - The inquiry transfer of Guangdong Wannianqing Pharmaceutical Co., Ltd. involved a maximum transfer of 8 million shares at a price of 18.80 CNY per share, reflecting a discount rate of 91.66% compared to the closing price on the pricing benchmark date [2][3]. Group 2: Participant Analysis - Private and public funds are the main participants in inquiry transfers, with private funds having the highest subscription frequency from 2020 to 2025, totaling 577 times [3]. - Public funds led with 82 subscriptions among licensed financial institutions, followed by QFII and securities companies with 43 and 60 subscriptions, respectively [3]. Group 3: Performance Metrics - As of February 11, 2026, 11 out of 12 companies that conducted inquiry transfers had stock prices above the initial transfer price, with some institutions achieving floating profits exceeding 30% [4]. - For example, Jiangbolong's inquiry transfer price was 212.09 CNY per share, while its stock price reached 284.14 CNY, resulting in a floating profit rate of approximately 34% [4]. Group 4: Comparative Analysis with Private Placements - Inquiry transfers have shown superior returns and discount performance compared to private placements, with an average return of 49.52% for inquiry transfers in 2025, surpassing the 38.61% return from competitive private placements [4][5]. - The number of companies conducting inquiry transfers increased from 12 in 2021 to 180 in 2025, indicating a growing acceptance of this method [5]. Group 5: Strategic Insights - Inquiry transfers and private placements complement each other by offering different risk-return profiles, attracting various investment strategies [5]. - The focus on sectors such as semiconductors, AI hardware, and domestic software is expected to enhance the visibility and growth certainty of leading companies, making their equity attractive assets [5].

Group 1 - The core viewpoint of the articles highlights the significant progress in antitrust reviews and the promotion of fair competition in China's market, with a focus on the efficiency of merger and acquisition (M&A) approvals [1][2] - In 2025, the State Administration for Market Regulation (SAMR) concluded 706 cases of operator concentration, marking a year-on-year increase of 9.8%, indicating a robust competitive market environment [1] - The average acceptance time for M&A cases was 17.9 days, and the average review time was 6.8 days, maintaining a leading position among major global jurisdictions [1] Group 2 - During the "14th Five-Year Plan" period, a total of 3,667 cases of operator concentration were concluded, involving transaction amounts of approximately 17.4 trillion yuan, with over 99% of concentrations being quickly approved [2] - The SAMR's approval of significant transactions, such as the conditional approval of the acquisition of Dole's equity by an American company, demonstrates its commitment to maintaining stability in the automotive supply chain [2] - The SAMR aims to create a fair and vibrant market environment through high-quality regulatory enforcement, promoting investment and M&A activities to strengthen the national unified market [2]

Core Insights - The investment community is increasingly focusing on inquiry transfers as a means to enhance capital efficiency, moving beyond traditional fixed increase projects [1] - A total of 12 listed companies have engaged in inquiry transfers since 2026, with notable participation from various public and private fund institutions [3] Group 1: Market Trends - Inquiry transfers have seen significant participation from both private and public funds, with private funds leading in subscription counts from 2020 to 2025, totaling 577 instances [4] - The number of companies conducting inquiry transfers has surged from 12 in 2021 to 180 by 2025, indicating a growing trend in this investment strategy [6] Group 2: Performance Metrics - Many institutions participating in inquiry transfers have reported substantial floating profits, with some exceeding 30% [5] - As of February 11, 2026, 11 out of 12 companies that conducted inquiry transfers had stock prices above their initial transfer prices, showcasing strong market performance [5] Group 3: Comparative Analysis - Inquiry transfers have demonstrated superior yield and discount performance compared to fixed increases, with an average return of 49.52% for inquiry transfers versus 38.61% for competitive fixed increases by the end of 2025 [5] - The average discount for inquiry transfers was 84.34%, outperforming the 86.88% for competitive fixed increases, highlighting the cost-effectiveness of this approach [5] Group 4: Strategic Implications - Inquiry transfers and fixed increases serve complementary roles in the market, attracting different investment strategies due to their distinct risk-return profiles [6] - Future investment strategies are expected to focus on sectors such as semiconductors, AI hardware, and domestic software, where the performance visibility and growth certainty of leading companies are significantly enhanced [6]

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiaries participated in the national procurement bidding for expiring products, with seven products, including Cefotaxime Sodium Injection, expected to be selected, which could significantly impact the company's revenue [1] Group 1: Company Announcement - Jincheng Pharmaceutical's subsidiary, Jincheng Jinsu, and its wholly-owned subsidiary, Jincheng Suzhi, are participating in the national procurement bidding for products whose agreements are expiring [1] - The seven products expected to be selected are projected to generate sales of 414 million yuan before the third quarter of 2025, accounting for 21.45% of the company's revenue [1] - The results of the selection are anticipated to be finalized by the end of March 2026, with the procurement cycle lasting until December 31, 2028 [1]

（编辑 丛可心） 证券日报网讯 2月11日，盘龙药业发布公告称，公司近日获国家药监局核准签发《药物临床试验批准通 知书》，同意酮洛芬凝胶贴膏开展镇痛临床试验。该化学药品3类规格14cm×10cm含酮洛芬30mg，拟用 于骨关节炎等局部镇痛，目前国内仅湖南九典制药获批上市。 ...